Showing results (641-650 of 682) with videos related to
Sort By:
Pageof 69
Blood|June 22, 2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaF E Davies, N Raje, T Hideshima, et al.The Journal of Biological Chemistry|November 11, 2017
Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8Michael H Matho, Andrew Schlossman, Iuliia M Gilchuk, et al.Current Developments in Nutrition|April 17, 2018
A Pilot Randomized Controlled Trial of a New Supplementary Food Designed to Enhance Cognitive Performance during Prevention and Treatment of Malnutrition in ChildhoodSusan B Roberts, Maria Angela Franceschini, Amy Krauss, et al.Leukemia|December 26, 2001
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsD Gupta, S P Treon, Y Shima, et al.Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Molecular mechanism for differential recognition of membrane phosphatidylserine by the immune regulatory receptor Tim4Gregory T Tietjen, Zhiliang Gong, Chiu-Hao Chen, et al.Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.Pageof 69